Genetia Biosciences, a pioneering biotech company located in the Prague Innovation Center, InnoCrystal and Lagom Pharmatech, located in Plzen, Czech Republic, have inked a significant three-year contract with Mar Medika, a Macedonian company specializing in medical cannabis cultivation and extraction. "This exclusive partnership is poised to reshape the landscape of medical cannabis production and research in Europe, with far-reaching implications for the future of healthcare."
Genetia Biosciences focuses on the mass production of in-vitro young cannabis plants. Based within the dynamic ecosystem of InnoCrystal, this biotech company has dedicated itself to pushing the boundaries of research and development. Collaborating closely with academic institutions, Genetia Biosciences remains at the forefront of cutting-edge advancements in plant sciences, cleantech, and best practices.
Lagom Pharmatech is a Czech pharmaceutical company specializing in the production and processing of premium, standardized medicinal substances derived from cannabis. These substances serve as a foundation for the preparation of individually tailored pharmaceutical products offered through pharmacies. Moreover, Lagom Pharmatech holds a crucial role as the largest licensed producer (LP) for the distribution of pharmaceuticals and the handling of narcotic drugs and preparations in Central Europe. The company boasts certifications of good manufacturing practice (EU-GMP) in the production of pharmaceutical substances, and it holds a license for cultivating cannabis plants for medicinal use. 
At the heart of their ambitious mission is the goal to scale up production to an astounding 40 million young cannabis plants within the next three years. Yet, their vision extends far beyond quantity alone. Genetia Biosciences is also expanding its molecular services, encompassing vital aspects such as plant pathogen detection, diagnostics, treatment, and various molecular breeding programs. 
Pioneers in the Macedonian cannabis industry
Mar Medika DOO, founded in 2018 as a 100% Macedonian investment, stands as a pioneer in the realm of medical cannabis cultivation. Specializing in the production of cannabis oil and APIs for medical purposes, this forward-looking company has made significant investments in creating a highly sophisticated facility designed to meet the rigorous standards of the medical cannabis industry. In its expansive 5000-square-meter internal cultivation area, Mar Medika utilizes an advanced, fully automated hydroponics system by KG Systems, ensuring precision and efficiency. One of the facility's standout features is its HEPA filtration walls, converting each cultivation room into a class D clean room. This innovation addresses critical concerns like contamination pressure and bio-burden (TYMC TAMC counts). The HVAC system incorporates patented technology from Munters, guaranteeing a clean and controlled environment.
The facility boasts modern equipment, including the Signify lighting system, clean rooms, and a molecular lab fully equipped by Thermofischer for comprehensive chemical and physical analysis. Moreover, Mar Medika operates an extraction facility utilizing supercritical CO2 and ethanol. Tools such as Buchi rotary evaporators and flash chromatography are employed for the separation of API molecules. To ensure quality standards, crude oil undergoes refinement in the 500-square-meter ISO 8 standard laboratory, employing modern fractional distillation systems. 
According to the companies, the collaboration between Genetia and Mar Medika represents a transformative venture within the medical cannabis industry. Their project encompasses diverse facets, including the production of 12-15 tons of medical cannabis and derivatives, the extraction of 10 tons of valuable extracts, and the cultivation of up to 20 million in-vitro young plants. Beyond these core activities, the project aims to co-develop ancillary services supporting the broader cannabis ecosystem, including molecular breeding programs enhancing cannabis strains.
In this dynamic partnership, Genetia and Mar Medika assume distinct yet complementary roles. Genetia spearheads critical aspects such as breeding programs, genetics provision, propagation, cultivation management, and sales. Their involvement is foundational to the project's success. Meanwhile, Mar Medika oversees operational activities, ensuring the day-to-day functionality of the project. Both partners collaborate on research & development (R&D) services, driving innovation and market excellence.
This strategic partnership underscores their commitment to synergy, leveraging each organization's strengths to achieve ambitious goals. "Together, we contribute significantly to the medical cannabis industry, spanning cultivation, research, and delivering high-quality cannabis products. In conclusion, the Genetia and Mar Medika partnership promises enduring benefits for all stakeholders. Our primary goal is delivering high-quality products to the market at competitive prices, coupled with streamlining operations and enhancing efficiency through automation and reduced labor costs. To achieve sustainable growth, addressing Europe's energy costs remains a pivotal challenge."
"In navigating this obstacle, Genetia and Mar Medika demonstrate an unwavering commitment to excellence and innovation in the medical cannabis sector. With a shared vision, defined responsibilities, and a determination to overcome challenges, this partnership stands poised to make a significant industry impact while delivering top-tier products to the market," the companies add.
For more information:
Genetia BioScience s.r.o.
[email protected]
www.genetia.cz
Lagom Pharmatech
www.lagompharmatech.com
Mar Medika DOO 
marmedika.com.mk